CLAIMS

1. A crystalline form of Compound A, wherein Compound A is *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide, and wherein the crystalline form is selected from:

Compound A Form 4, wherein the crystalline form is characterized by one or more peaks in an XRPD pattern selected from 13.62, 14.16, 14.61, 18.44, 19.93, 22.97, and 23.73 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ;

Compound A Form 2, wherein the crystalline form is characterized by one or more peaks in an XRPD pattern selected from 5.51, 11.01, 11.53, 14.91, 16.54, 19.17, 20.83, 21.48, 22.68, and 24.18 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ;

Compound A Form 9, wherein the crystalline form is characterized by one or more peaks in an XRPD pattern selected from 3.05, 6.107, 10.69, 15.33, 18.08, 20.98, 23.49, and 25.25 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ; and

Compound A Form 11, wherein the crystalline form is characterized by one or more peaks in an XRPD pattern selected from 11.40, 11.69, 15.08, 19.48, 20.52, 21.40, 22.47, 23.44, and 23.61 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

2. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 2 characterized by three or more peaks in an XRPD pattern selected from 5.51, 11.01, 11.53, 14.91, 16.54, 19.17, 20.83, 21.48, 22.68, and 24.18 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

3. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 2 characterized by four or more peaks in an XRPD pattern selected from 5.51, 11.01, 11.53, 14.91, 16.54, 19.17, 20.83, 21.48, 22.68, and 24.18 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

4. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 2 characterized by five or more peaks in an XRPD pattern selected from 5.51, 11.01,

11.53, 14.91, 16.54, 19.17, 20.83, 21.48, 22.68, and 24.18 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

5. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 2 characterized by the following peaks in an XRPD pattern: 5.51, 11.01, 11.53, 14.91, 16.54, 19.17, 20.83, 21.48, 22.68, and 24.18 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

6. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 2 characterized by three or more peaks in an XRPD pattern selected from: 5.51, 11.01, 16.54, 19.17, 22.68, and 24.18 degrees 2θ ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

7. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 2 characterized by four or more peaks in an XRPD pattern selected from: 5.51, 11.01, 16.54, 19.17, 22.68, and 24.18 degrees 2θ ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

8. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 2 characterized by the following peaks in an XRPD pattern: 5.51, 11.01, 16.54, 19.17, 22.68, and 24.18 degrees 2θ ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

9. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 2 characterized by the following peaks in an XRPD pattern: 5.51, 16.54, and 24.18 degrees 2θ ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

10. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 4 characterized by three or more peaks in an XRPD pattern selected from 13.62, 14.16, 14.61, 18.44, 19.93, 22.97, and 23.73 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

11. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 4 characterized by four or more peaks in an XRPD pattern selected from 13.62, 14.16, 14.61, 18.44, 19.93, 22.97, and 23.73 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

12. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 4 characterized by five or more peaks in an XRPD pattern selected from 13.62, 14.16, 14.61, 18.44, 19.93, 22.97, and 23.73 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

13. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 4 characterized by the following peaks in an XRPD pattern: 13.62, 14.16, 14.61, 18.44, 19.93, 22.97, and 23.73 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

14. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 4 characterized by the following peaks in an XRPD pattern: 14.61, 18.44, and 22.97 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

15. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 4 characterized by the following peaks in an XRPD pattern: 13.62, 14.61, and 22.97 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

16. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 4 characterized by the following peaks in an XRPD pattern: 13.62, 14.61, and 22.97 degrees 2θ ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

17. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 4 characterized by the following peaks in an XRPD pattern: 13.62, 14.16, and 19.93 degrees 2θ ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

18. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 9 characterized by three or more peaks in an XRPD pattern selected from 3.05, 6.107, 10.69, 15.33, 18.08, 20.98, 23.49, and 25.25 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

19. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 9 characterized by four or more peaks in an XRPD pattern selected from 3.05, 6.107,

10.69, 15.33, 18.08, 20.98, 23.49, and 25.25 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

20. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 9 characterized by five or more peaks in an XRPD pattern selected from 3.05, 6.107, 10.69, 15.33, 18.08, 20.98, 23.49, and 25.25 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

21. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 9 characterized by the following peaks in an XRPD pattern: 3.05, 6.107, and 25.25 degrees 2θ ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

22. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 11 characterized by three or more peaks in an XRPD pattern selected from 11.40, 11.69, 15.08, 19.48, 20.52, 21.40, 22.47, 23.44, and 23.61 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

23. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 11 characterized by four or more peaks in an XRPD pattern selected from 11.40, 11.69, 15.08, 19.48, 20.52, 21.40, 22.47, 23.44, and 23.61 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

24. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 11 characterized by five or more peaks in an XRPD pattern selected from 11.40, 11.69, 15.08, 19.48, 20.52, 21.40, 22.47, 23.44, and 23.61 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

25. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 11 characterized by the following peaks in an XRPD pattern: 11.40, 11.69, 15.08, 19.48, 20.52, 21.40, 22.47, 23.44, and 23.61 degrees 2θ ± 0.3 degrees 2θ, ± 0.2 degrees 2θ, ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

26. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 11 characterized by the following peaks in an XRPD pattern: 19.48, 20.52, and 22.47 degrees 2θ ± 0.1 degrees 2θ, or ± 0.05 degrees 2θ.

27. The crystalline form according to claim 1, wherein the crystalline form is Compound A Form 11 characterized by the following peaks in an XRPD pattern: 11.40, 11.69, 15.08, 19.48, 20.52, 22.47, and 23.61 degrees 2θ ± 0.05 degrees 2θ.

28. The crystalline form according to any preceding claim, wherein each peak is ± 0.2 degrees 2θ.

29. The crystalline form according to any preceding claim, wherein each peak is ± 0.1 degrees 2θ.

30. The crystalline form according to any preceding claim, wherein each peak is ± 0.05 degrees 2θ.

31. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the crystalline form of any one of claims 1-30.

32. The pharmaceutical composition according to claim 31, wherein the crystalline form is Compound A Form 2, wherein the composition is substantially free of any other crystalline form of Compound A.

33. The pharmaceutical composition according to claim 31, wherein the crystalline form is Compound A Form 4, wherein the composition is substantially free of any other crystalline form of Compound A.

34. The pharmaceutical composition according to claim 31, wherein the crystalline form is Compound A Form 9, wherein the composition is substantially free of any other crystalline form of Compound A.

35. The pharmaceutical composition according to claim 31, wherein the crystalline form is Compound A Form 11, wherein the composition is substantially free of any other crystalline form of Compound A.

36. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a mixture of two or more crystalline forms of any one of claims 1-30.

37. Use of the crystalline form of any one of claims 1-30, or pharmaceutical composition of any one of claims 31-36 in the manufacture of a medicament for treating a seizure disorder in a human in need thereof.

38. The use of claim 37, wherein the human is to be treated with the crystalline form of Compound A from between 30 minutes before and 2 hours after eating a meal.

39. The use of claim 37, wherein the human is to be treated with the crystalline form of Compound A during a meal or within 15 minutes after eating a meal.

40. The use of any one of claims 37-39, wherein the seizure disorder is partial onset (focal) seizures.

41. The use of any one of claims 37-40, wherein the medicament comprises 5-50 mg of Compound A.

42. The use of any one of claims 37-41, wherein the medicament comprises 10-30 mg of Compound A.

43. The use of any one of claims 37-42, wherein the medicament comprises 10, 15, 20, 25, or 30 mg of Compound A.

44. The use of any one of claims 37-43, wherein the medicament is to be administered to provide 10-30 mg of Compound A per day as a single dose.

45. A method of preparing a pharmaceutical composition comprising a pharmaceutical excipient and a crystalline form of Compound A, the method comprising combining the

crystalline form of any one of claims 1-30 with the pharmaceutical excipient to form the pharmaceutical composition.